Clinical Trial Update: Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and immunogenicity of the human cytomegalovirus vaccine V160 in healthy adults has been completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• V160 (human cytomegalovirus vaccine V160)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cytomegalovirus Infections | Phase 1 | Status: COMPLETED | Results posted: 2021-11-01